psoriasis Clinical Trials Update: Week 13, 2026

Published March 29, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

This Phase 3 trial is exploring deucravacitinib, an oral medication, in adolescents aged 12 to under 18 with moderate to severe plaque psoriasis. It aims to offer a new treatment that may be easier to take and have a better safety profile compared to current options. If successful, this could provide younger patients with a convenient alternative to injections or creams.

The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease

This Phase 4 study is examining whether reducing salt intake can lower sodium levels in the skin and improve symptoms of psoriasis and atopic dermatitis. The trial lasts 13 weeks and is recruiting adults in the United States. Findings could support dietary changes as a helpful way to manage psoriasis alongside medical treatments.

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

This Phase 3 trial tested bimekizumab, a biologic drug, in adults with moderate to severe plaque psoriasis. The study is now complete and results suggest this treatment may improve skin symptoms and overall disease control. Bimekizumab could become a valuable option for adults seeking relief from persistent plaque psoriasis.

A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis

This Phase 3 study is focusing on tildrakizumab injections for adults with moderate to severe genital psoriasis, a form that can be difficult to treat. The trial is active but not recruiting, and aims to provide a treatment that improves symptoms and quality of life in this sensitive area. Success here would address an important need for targeted therapies.

Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

This Phase 3 trial assessed imsidolimab, an immunotherapy drug, for generalized pustular psoriasis, a rare and severe form of the condition. Results have been reported and suggest potential benefits in managing this challenging disease. This research may help expand treatment options for patients with this serious psoriasis type.

Research continues to advance in many areas of psoriasis treatment, from new medications to lifestyle factors like diet. Although these studies show promise, it is important to remember that new treatments will need time for thorough testing and approval. Working closely with healthcare providers remains the best way to manage psoriasis today while staying informed about emerging options for the future.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report for psoriasis this week. Get weekly briefings at trialsalert.com.